Upsher-Smith has announced that it has completed the acquisition of two Dr. Reddy's treatments of acute migraine for adults. This strategic acquisition of 3mg Zembrace Symtouch (sumatriptan injection) and 10mg Tosymra (sumatriptan nasal spray) is expected to expand and diversify Upsher-Smith’s portfolio.
Confirming the completion, Rusty Field, president and CEO of Upsher-Smith, stated that "more than 36 million Americans suffer from migraines, and Upsher-Smith is proud to be diversifying the portfolio with two products that can bring
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?